IDEAYA Biosciences, Inc. Common Stock
IDYAIDEAYA Biosciences, Inc. is a clinical-stage biotechnology company focused on developing targeted therapies for cancer. The company leverages insights from tumor genetics and tumor immune profiling to create precision medicines aimed at improving outcomes for patients with various cancers. Founded in 2015, IDEAYA is based in South San Francisco, California, and emphasizes innovative approaches in oncology treatments.
Company News
The global antibody optimization service market is projected to grow from USD 2.77 billion in 2024 to USD 6.07 billion by 2034, driven by advances in gene-editing technologies, AI/computational tools, and increasing biologics R&D.
Over 150 pharmaceutical companies are actively developing 170+ pipeline melanoma drugs, with promising therapies in various clinical trial stages targeting improved treatment outcomes through immunotherapies and targeted treatments.
IDEAYA Biosciences reported a Q2 2025 net loss of $0.88 per share with no revenue, but maintained strong cash reserves of $991.9 million. The company continues advancing its cancer therapy pipeline, with key clinical trials progressing in darovasertib and other oncology programs.
The melanoma market is expected to surge between 2025-2034 due to increasing incidence, emerging therapies, heightened UV exposure, and diagnostic advancements. Several new therapies are in development, with potential to transform treatment options for melanoma patients.
Kura Sushi USA reported weak Q3 results, missing analyst estimates. Several other companies, including LegalZoom.com, Stardust Power, 10x Genomics, IDEAYA Biosciences, and uniQure, also saw their shares decline in pre-market trading.
